Unigene Laboratories Inc. (OTCBB: UGNE)

Unigene Laboratories is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and parathyroid hormone- based therapies. The Company’s first U.S. Product, Fortical®, was approved and launched in August 2005. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, parathyroid hormone and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. Pharmaceutical partners include GlaxoSmithKline, Upsher-Smith Laboratories and Novartis. Unigene has also developed Site-Directed Bone Growth technology which may be able to repair damaged bone, potentially representing a minimally invasive procedure to prevent and treat hip and vertebral compression fractures.

In the News

Dr. Warren Levy, CEO and Founder of Unigene Laboratories, is interviewed for In Full View News TV -
Dr. Warren Levy, CEO and Founder of Unigene Laboratories, is interviewed for In Full View News TV and provides a look at how the New Jersey biopharmaceutical company is advancing peptide therapies. (Watch)
Unigene Laboratories Answer to the Obesity Epidemic in America -
A recent study in The American Journal of Health found that America’s obesity epidemic now poses a threat to health-related quality of life as severe as tobacco use. This surprising result, combined with estimates by the National Institutes of Health that almost one-third of the US population is already obese, implies that the US is well on its way to a frightening health crisis.
Options for Bone Loss, but No Magic Pill -
A reader recently complained that her elderly mother had faithfully taken the medication prescribed to protect her osteoporotic bones from fracture but still broke her hip as she walked from her bedroom to the bathroom one morning. The older woman recalled that she had felt her hip give way and then fell, not the other way around.
Independent Advisory Committee Recommends Continuation of Phase III Oral Calcitonin Studies For Osteoporosis And Osteoarthritis -
Unigene Laboratories, Inc. (OTCBB: UGNE) announced that an independent Data Monitoring Committee (DMC) has recommended that Novartis and its partner Nordic Bioscience proceed as planned with their ongoing oral calcitonin Phase III studies for osteoporosis and osteoarthritis.
Unigene Licenses Phase III Oral Calcitonin Program To Tarsa Therapeutics -
Unigene Laboratories, Inc. (OTCBB: UGNE) and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.